Neoadjuvant T-DXd Active in HER2-Low Breast Cancer

(MedPage Today) -- SAN ANTONIO--Use of trastuzumab deruxtecan (T-DXd, Enhertu) in patients with localized, hormone receptor (HR)-positive, HER2-low breast cancer demonstrated evidence of clinical activity in the neoadjuvant setting, according...